Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

Villa, Luisa L.; Ault, Kevin A.; Giuliano, Anna R.; Costa, Ronaldo; Petta, Carlos Alberto; Andrade, Rosíres Pereira de; Brown, Darron R.; Ferenczy, Alex; Harper, Diane M.; Koutsky, Laura A.; Kurman, Robert J.; Lehtinen, Matti; Malm, Christian; Olsson, Sven Eric; Ronnett, Brigitte M.; Skjeldestad, Finn Egil; Steinwall, Margareta; Stoler, Mark H.; Wheeler, Cosette M.; Taddeo, Frank J.; Yu, Jimmy; Lupinacci, Lisa; Railkar, Radha; Marchese, Rocio D.; Esser, Mark T.; Bryan, Janine T.; Jansen, Kathrin U.; Sings, Heather L.; Tamms, Gretchen; Saah, Alfred J.; Barr, Eliav

doi:10.1016/j.vaccine.2006.04.068

Cited by 403 publications

(318 citation statements)

References 33 publications

Supporting

Mentioning

268

Contrasting

Unclassified

Order By: Relevance

“…However, the distributions of the European prototype and European variants in northeast China were specific, because the data were different from data of any other area by statistical analysis. Identification of HPV 16 variants may be helpful to evaluate the potential impact of HPV vaccine and design diagnostics and therapeutic methods on cervical cancer (15,44). Although further confirmation of this study is still needed, the results may be helpful for the study of the HPV vaccination program in China.…”

Section: Discussionmentioning

confidence: 72%

Human Papillomavirus Type 16 Variant Analysis of E6, E7, and L1 Genes and Long Control Region in Identification of Cervical Carcinomas in Patients in Northeast China

et al. 2011

View full text Add to dashboard Cite

Human papillomavirus type 16 (HPV 16) is the primary etiology of cervical cancer, which is the second most common type of cancer in women worldwide (29). HPV 16 variants, which vary by Յ2% from HPV 16 prototype nucleotide sequences, have been identified as the following six phylogenetic branches: European (E), Asian (As), Asian-American (AA), African-1 (Af-1), African-2 (Af-2), and northern American (NA) variants (18,52). Several researchers had reported correlations between specific HPV 16 variants and persistent viral infection, followed by the development of malignant lesions (3,4,16,37,43,49,50). Non-European variants were found to be associated with an excess risk of cervical cancer (37). These variants had been found to show different geographic distributions, while some sequence variations had oncogenic potentials. In HPV 16 variants, the L83V mutation in E6 in the Swedish and Italian populations and D25E in E6 in the Japanese population were reported to be associated with the

show abstract

Section: Discussionmentioning

confidence: 72%

Human Papillomavirus Type 16 Variant Analysis of E6, E7, and L1 Genes and Long Control Region in Identification of Cervical Carcinomas in Patients in Northeast China

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Findings from pre-clinical and clinical HPV L1 VLP vaccine studies suggest that neutralizing antibodies constitute the primary mechanism of protection against infection with HPV [6,10,14,15,31]. Several assays have been developed to measure antibody responses to HPV vaccines [16][17][18][19], and in this report we have directly compared two of these assays, the HPV16/18 L1 VLP-based ELISA and SEAP-NA.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women

Kemp¹,

Garcı́a-Piñeres²,

Falk³

et al. 2008

Vaccine

106

View full text Add to dashboard Cite

Ideal methods to monitor HPV neutralizing antibodies induced by vaccination have not been established yet. Here, we evaluated systemic and cervical antibody levels induced by HPV16/18 AS04-adjuvanted vaccine (GlaxoSmithKline Biologicals) using a secreted alkaline phosphatase neutralization assay (SEAP) and ELISA. Serum and cervical secretions from 50 vaccinated women were used to assess 1) overall assay reproducibility, 2) inter-assay and inter-specimen correlation; 3) correlations between month 1 and month 12 titers. Strong correlations between SEAP-NA and ELISA were observed (serum anti-HPV16/18, ρ=0.91/0.85; cervix anti-HPV16/18, ρ=0.84/0.89). Systemic and cervical antibody measures also correlated well (ρ range: 0.64 -0.75); except at mid-cycle (ρ range: 0.28 -0.65). Correlations between antibody levels at one and twelve months following the start of vaccination were poor (ρ range: 0.16 -0.38). In conclusion, HPV16/18 VLP-based ELISA is a reliable and valid method to monitor anti-HPV16/18 neutralizing potential for the first year following vaccination; however, additional studies will be Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.Conflict of Interest: Troy J. Kemp, no conflict; Alfonso García-Piñeres, no conflict; Roni T. Falk, no conflict; Sylviane Poncelet is employed by GSK Biologicals, the manufacturer of the vaccine used in this trial; Francis Dessy is employed by GSK Biologicals, the manufacturer of the vaccine used in this trial; Sandra L. Giannini is employed by GSK Biologicals, the manufacturer of the vaccine used in this trial; Ana Cecilia Rodriguez, no conflict; Carolina Porras, no conflict; Rolando Herrero, no conflict; Allan Hildesheim, no conflict; Ligia A. Pinto, no conflict. Merocel is a trademark of Medtronic Ophthalmics, a division of Medtronic Xomed, Inc., Jacksonville, FL, and Hemastix is a trademark of Bayer Corporation, Elkhart, IN. NIH Public Access Author ManuscriptVaccine. Author manuscript; available in PMC 2014 August 13.

show abstract

“…[16][17][18] Previous studies have shown that the HPV6/11/16/18 vaccine generates an anamnestic response in women who are seropositive to vaccine HPV types prevaccination ( Fig. 1) 19,20 and prevents reinfection or reactivation of disease that is related to vaccine HPV types. 21 In contrast, the HPV6/11/16/18 vaccine does not impact progression of HPV16 or HPV18 infections to disease (i.e., there was no impact in women who were seronegative and DNA positive to HPV16 or HPV18).…”

mentioning

confidence: 99%

“…Seventeen thousand six-hundred and twenty-two women aged [16][17][18][19][20][21][22][23][24][25][26] were enrolled in 1 of 2 randomized, placebo-controlled, efficacy trials (Protocols 013 and 015). Vaccine or placebo was given at day 1, month 2 and 6.…”

mentioning

confidence: 99%

Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection

Haupt¹,

Wheeler²,

Brown

et al. 2011

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

The impact of a human papillomavirus (HPV) vaccine on development of cervical intraepithelial neoplasia grade 2‐3 or adenocarcinoma in situ (CIN2‐3/AIS) in women with ongoing HPV16 or 18 infections prevaccination is reported. Seventeen thousand six‐hundred and twenty‐two women aged 16–26 were enrolled in 1 of 2 randomized, placebo‐controlled, efficacy trials (Protocols 013 and 015). Vaccine or placebo was given at day 1, month 2 and 6. Women were tested for HPV6/11/16/18 DNA and antibodies at day 1. We focus on the subset of women who were seropositive and DNA positive to HPV16 or HPV18 prevaccination. Incidence is expressed as the number of women with an endpoint per 100 person‐years‐at‐risk. In total, 419 vaccine and 446 placebo recipients were both seropositive and DNA positive to HPV16 or HPV18 prevaccination and had at least one follow‐up visit. In Protocol 013, the incidence of HPV16/18‐related CIN2‐3/AIS among these women was 10.9 in the vaccine arm and 7.0 in the placebo arm (vaccine efficacy = −54.9; 95% CI: −181.7, 13.0). In Protocol 015, the incidence of HPV16/18‐related CIN2‐3/AIS was 5.5 in the vaccine arm and 6.2 in the placebo arm (vaccine efficacy = 12.2%; 95% CI: −29.8, 40.9). These data suggest HPV vaccination neither reduces nor enhances progression to HPV16/18‐related high grade cervical lesions, and cervical cytology screening and corresponding management should continue as per local recommendations. Ultimately, population‐based surveillance of vaccinated individuals beyond these clinical trials will be required to further address questions regarding the impact of vaccination in women exposed to vaccine HPV types before vaccination.

show abstract

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

Cited by 403 publications

References 33 publications

Human Papillomavirus Type 16 Variant Analysis of E6, E7, and L1 Genes and Long Control Region in Identification of Cervical Carcinomas in Patients in Northeast China

Human Papillomavirus Type 16 Variant Analysis of E6, E7, and L1 Genes and Long Control Region in Identification of Cervical Carcinomas in Patients in Northeast China

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women

Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection

Contact Info

Product

Resources

About